Table 2.

Summary of adverse events (MedDRA preferred term) occurring in ≥ 2 participants per cohort in healthy participants (part A) or patients with psoriasis (part B)

Part A: Healthy participants (N = 40) a	Placebo (n = 14)	GSK2831781
		0.0075 mg/kg (ADA‐ve) (n = 6)	0.04 mg/kg (ADA‐ve) (n = 6)	0.15 mg/kg (ADA‐ve) (n = 6)	0.15 mg/kg (ADA + ve) (n = 6)	0.15 mg/kg (combined) (n = 12)	Total (n = 24)
Any event, n (%)	8 (57)	5 (83)	6 (100)	3 (50)	3 (50)	6 (50)	17 (65)
Headache, n (%)	2 (14)	1 (17)	3 (50)	0	1 (17)	1 (8)	5 (19)
Back pain, n (%)	2 (14)	1 (17)	0	0	2 (33)	2 (17)	3 (12)
Nasopharyngitis, n (%)	2 (14)	0	2 (33)	1 (17)	0	1 (8)	3 (12)
Abdominal pain, n (%)	0	3 (50)	0	0	0	0	3 (12)
Oropharyngeal pain, n (%)	0	2 (33)	0	0	1 (17)	1 (8)	3 (12)

Part B: Patients with psoriasis (N = 27)	Placebo (n = 9)	GSK2831781
		0.5 mg/kg (n = 6)	1.5 mg/kg (n = 6)	5 mg/kg (n = 6)	Total (n = 18)
Any event, n (%)	9 (100)	4 (67)	6 (100)	6 (100)	16 (89)
Headache, n (%)	4 (44)	1 (17)	3 (50)	2 (33)	6 (33)
Nasopharyngitis, n (%)	3 (33)	2 (33)	2 (33)	2 (33)	6 (33)
Back pain, n (%)	0	2 (33)	1 (17)	3 (50)	6 (33)
Oral herpes, b n (%)	1 (11)	2 (33)	0	1 (17)	3 (17)
Diarrhea, n (%)	1 (11)	2 (33)	0	0	2 (11)
Oropharyngeal pain, n (%)	0	0	2 (33)	0	2 (11)
Post‐procedural inflammation, c n (%)	0	0	0	2 (33)	2 (11)

ADA, anti‐drug antibodies; ADA‐ve, ADA negative; ADA + ve, ADA positive; AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities.

^aNo AEs were reported for cohorts 1 (0.0003 mg/kg, n = 1) and 2 (0.0015 mg/kg, n = 1).

^bThree of 18 (17%) patients receiving GSK2831781 reported oral herpes infection, and 3 of 9 (33%) placebo‐treated patients reported AEs of oral herpes, herpes zoster, and ophthalmic herpes zoster.

^cRelated to skin biopsy site.